Evidence map›Paper›PMID 41721353›Full record

ArticleBMC veterinary research2026

Aloperine alleviates LPS-induced inflammation in bovine intestinal epithelial cells through autophagy and TLR4/p38 MAPK/NF-κB pathway.

Panpan Tan, Yazhou Wang, Cai Zhang, Qinghua Deng, Liyin Du, Baoyu Zhao, Gulman Muhametbay, Chenxu Zhao, Jianguo Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Panpan Tan *College of Animal Science and Technology, Inner Mongolia Minzu University, Tongliao, 028000, China.
Yazhou Wang *College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, 712100, China.
Cai ZhangCollege of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471023, China.
Qinghua DengCollege of Animal Science and Technology, Inner Mongolia Minzu University, Tongliao, 028000, China.
Liyin DuCollege of Animal Science and Technology, Inner Mongolia Minzu University, Tongliao, 028000, China.
Baoyu ZhaoCollege of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, 712100, China.
Gulman MuhametbayAnimal Disease Prevention and Control Center of Xinjiang, Urumqi, 830000, China.
Chenxu ZhaoCollege of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, 712100, China. cxzhao@nwafu.edu.cn.
Jianguo WangCollege of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, 712100, China. jgwang0625@nwsuaf.edu.cn.

Funding

General Program of China Postdoctoral Science Foundation 2023M732887Inner Mongolia Minzu University BSZ033National Natural Science Foundation of China 32273085National Natural Science Foundation of China 32560881Natural Science Foundation of Inner Mongolia Autonomous Region 2025MS03060Natural Science Foundation of Inner Mongolia Autonomous Region of China 2025QN03056Shaanxi Province Postdoctoral Science Foundation 2023BSHEDZZ148
6 · The paper itself

Abstract

backgroundCalf diarrhea is a major cause of mortality and morbidity, leading to substantial economic losses in the cattle industry. Aloperine (Alo) exhibits an anti-inflammation effect and alleviates dextran sulfate sodium salt (DSS)-induced colitis; however, it remains unclear whether Alo alleviates calf diarrhea-induced intestinal inflammation.

resultsIn this study, network pharmacology was used to discover the possible mechanism of Alo on the anti-inflammatory effect; Then, an inflammation model was induced by LPS in BIECs-21 to evaluate the protective effect of Alo on LPS-induced inflammation. Results found that a total of 68 overlapping targets of Alo and inflammation were obtained, among which ALB, AKT1, IL-6, and EGFR exhibited good affinity for Alo. In vitro experiments, Alo inhibited LPS-induced pro-inflammatory cytokine levels, increased the expression of ZO-1 and Claudin 1, and reduced the expression of proteins related to autophagy and TLR4/p38 MAPK/NF-κB pathway; the autophagy inhibitor CQ and Baf A1 results further demonstrated that Alo inhibited late stages of autophagy maturation and impaired intestinal epithelial barrier function.

conclusionsThese results indicated that Alo has protective effects on LPS-induced inflammation by decreasing the levels of the pro-inflammatory cytokines through the TLR4/p38 MAPK/NF-κB pathway, inhibiting late stages of autophagy maturation, and impairing intestinal epithelial barrier function.

Indexed as

Anti-Inflammatory AgentsAutophagyInflammationAnimalsCattleCell LineEpithelial CellsIntestinal MucosaLipopolysaccharidesNF-kappa Bp38 Mitogen-Activated Protein KinasesSignal TransductionToll-Like Receptor 4Anti-Inflammatory AgentsLipopolysaccharidesNF-kappa Bp38 Mitogen-Activated Protein KinasesToll-Like Receptor 4AloperineAutophagyCalf diarrheaInflammationNetwork pharmacology

Identifiers

PMID41721353
PMCPMC13032521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.